Effects of Competition on Drug-Product Selection

Paul G. Grussing, Jesse E. Stewart, Michael Dickson, P. David Jarry, John E. Kralewski, Laura Pitt, Bryan Dowd

Research output: Contribution to journalLetterpeer-review

Abstract

To the Editor: Three flaws in the study by Kralewski et al. (July 28 issue)1 render its hypotheses questionable, reduce the internal and external validity, and do not permit the data to support the conclusions drawn. First of all, the study is based on the notion that pharmacists' drug-product–selection behaviors can be explained by using two categories of drugs: “generic drug products” and “brand-name drug products.” Such a classification is neither logical nor definitive. A useful classification, permitting meaningful comparisons, identifies each drug entity as containing single-source or multiple-source drug products. Single-source drug products are so classified because they are.

Original languageEnglish (US)
Pages (from-to)1585-1587
Number of pages3
JournalNew England Journal of Medicine
Volume309
Issue number25
DOIs
StatePublished - Dec 22 1983

Fingerprint

Dive into the research topics of 'Effects of Competition on Drug-Product Selection'. Together they form a unique fingerprint.

Cite this